A5011049799- Pharmaceutical Economics and Policy
- Health Systems, Economic Evaluations, Quality of Life
- Biosimilars and Bioanalytical Methods
- SARS-CoV-2 and COVID-19 Research
- Biotechnology and Related Fields
- Biomedical and Engineering Education
- Statistical Methods in Clinical Trials
- COVID-19 Clinical Research Studies
- vaccines and immunoinformatics approaches
- RNA Interference and Gene Delivery
- Intellectual Property and Patents
- Medical Research and Treatments
- Frailty in Older Adults
- Inflammatory Bowel Disease
- Human Health and Disease
- Global Health Care Issues
- Hidradenitis Suppurativa and Treatments
- Science, Research, and Medicine
- Neutropenia and Cancer Infections
- Celiac Disease Research and Management
- Diabetes and associated disorders
- Biomedical Ethics and Regulation
- Technology Assessment and Management
- Monoclonal and Polyclonal Antibodies Research
- Innovation Policy and R&D
Pfizer (United States)
2012-2025
John Wiley & Sons (United States)
2016-2020
New York Academy of Sciences
2016-2020
Hudson Institute
2016-2020
Albert Einstein College of Medicine
2019-2020
Montefiore Medical Center
2019-2020
Icahn School of Medicine at Mount Sinai
2019
Charité - Universitätsmedizin Berlin
2017
Institut Català de Ciències del Clima
2016
Abstract The US healthcare system is at a crossroads. With an aging population requiring more care and strained facing workforce shortages, capacity issues, fragmentation, innovative solutions policy reforms are needed. This paper aims to spark dialogue collaboration among stakeholders inspire action meet the needs of population. Through comprehensive analysis impact society, this work highlights urgency addressing issue importance restructuring be efficient, equitable, responsive.
Abstract In the past decade, RNA therapeutics have gone from being a promising concept to one of most exciting frontiers in healthcare and pharmaceuticals. The field is now entering what many call renaissance or “RNAissance” which fueled by advances genetic engineering delivery systems take on more ambitious development efforts. However, this occurring at an unprecedented pace, will require different way thinking if live up its full potential. Recognizing need, article provide...
Abstract A patient with B-cell acute lymphoblastic leukemia (ALL) and severe respiratory syndrome coronavirus 2 (SARS-CoV-2) had persistent, progressive pneumonia viremia after 5 months of infection despite monoclonal antibodies, intravenous (IV) remdesivir prolonged oral steroids. Twenty days nirmatrelvir/ritonavir 10 IV led to full recovery.
Over the past decade, Pfizer has focused efforts to improve its research and development (R&D) productivity. By end of 2020, had achieved an industry-leading clinical success rate 21%, a tenfold increase from 2% in 2010 well above industry benchmark ∼11%. The company also maintained quality innovation, because 75% approvals between 2016 2020 at least one expedited regulatory designation (e.g., Breakthrough Therapy). Pfizer's Signs Clinical Activity (SOCA) paradigm enabled better...
The SARS-CoV-2 infection triggered a global pandemic in 2020, and the identification of safe effective oral antiviral treatments was critical fight against COVID-19. Here, we describe our adaptive approach to developing nirmatrelvir/ ritonavir (Paxlovid) treat Yu et al. challenges faced rapid development upscaling Paxlovid meet demand for COVID-19 treatment. They respond by investing at risk, integrating predictive tools strategy, implementing diversified supply chain.
Master protocol designs, such as umbrella and basket studies, allow multiple compounds or target populations to be evaluated simultaneously within a single protocol, have been widely adopted in oncology clinical trials. These novel designs can also applied other therapeutic areas, where they could several benefits over conducting traditional randomized controlled Here, we detail Pfizer's recent implementations of master inflammation immunology focusing on the opportunities for cost resource...